Back to search

Article

Deubiquitinating Enzyme Inhibitor Alleviates Cyclin A1-mediated Proteasome Inhibitor Tolerance in Mixed-lineage Leukemia

2020-12-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Drug resistance is a significant obstacle to effective cancer treatment. Drug resistance develops from initially reversible drug-tolerant cancer cells, which offers therapeutic opportunities to impede cancer relapse. The mechanisms of resistance to proteasome inhibitor (PI) therapy have been investigated intensively; however, the ways by which drug-tolerant canc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
97bf75f7-4e16-56f8-be12-99293605ce05
DOI
10.21203/rs.3.rs-125310/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Deubiquitinating Enzyme Inhibitor Alleviates Cyclin A1-mediated Proteasome Inhibitor Tolerance in Mixed-lineage LeukemiaDOI 10.21203/rs.3.rs-125310/v1
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistanceSemantic proximity
Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity
Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity
Drug Resistance in Non-Hodgkin LymphomasSemantic proximity
Protein degradation: expanding the toolbox to restrain cancer drug resistanceSemantic proximity
CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.Semantic proximity
Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): A feature of B-CLL sub-sets with poor prognosis genetic alterations?Semantic proximity
Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsSemantic proximity
Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphomaSemantic proximity
Select a neighboring publication to make it the new centre.